The M. tuberculosis strains were obtained from clinical specimens collected from TB patients at the Moscow Research and Clinical Center for Tuberculosis Control. In total, 349 clinical isolates, obtained in 2016–2020 from patients who attended the Moscow Research and Clinical Center for Tuberculosis Control were analyzed: 2016—50 isolates, 2017—87 isolates, 2018—66 isolates, 2019—74 isolates, and 202—72 isolates. For molecular analysis only primary isolates from 2017–2018 were used. They were isolated sequentally, one isolate for one patient, before treatment initiation. Drug susceptibility testing for rifampicin, isoniazid, streptomycin, ethambutol, pyrazinamide, ofloxacin, moxifloxacin, kanamycin, capreomycin, and amikacin, PAS, ethionamide was performed using Bactec MGIT 960 as previously described [45 ,46 ]. Sensititre MYCOTB MIC determination was performed as described in [47 (link)].
The study was approved by the Ethics Committee of the Moscow Government Health Department. The Ethics Committee waived the need for patient consent because the study did not include personal identifiers or clinical data and the samples were analyzed anonymously.
The study was approved by the Ethics Committee of the Moscow Government Health Department. The Ethics Committee waived the need for patient consent because the study did not include personal identifiers or clinical data and the samples were analyzed anonymously.
Free full text: Click here
